(XMVM) S&P MidCap Value with - Overview
Etf: Mid-Cap, Value, Momentum, Equity, Diversified
Dividends
| Dividend Yield | 2.28% |
| Yield on Cost 5y | 3.55% |
| Yield CAGR 5y | 25.24% |
| Payout Consistency | 93.8% |
| Payout Ratio | - |
| Risk 5d forecast | |
|---|---|
| Volatility | 17.3% |
| Relative Tail Risk | -4.95% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.91 |
| Alpha | 9.38 |
| Character TTM | |
|---|---|
| Beta | 0.900 |
| Beta Downside | 0.945 |
| Drawdowns 3y | |
|---|---|
| Max DD | 24.12% |
| CAGR/Max DD | 0.64 |
Description: XMVM S&P MidCap Value with December 30, 2025
The Invesco S&P MidCap Value with Momentum ETF (NYSE ARCA: XMVM) is mandated to allocate at least 90% of its assets to the 80 stocks selected from the S&P MidCap 400® Index that score highest on combined value and momentum metrics. The index construction follows strict, pre-published guidelines, and the ETF’s holdings are intended to track the index’s performance closely.
As of the most recent filing (Q3 2024), XMVM carries an expense ratio of 0.35%, a distribution yield of roughly 1.8%, and its top sector exposures are Financials (≈28%), Industrials (≈22%) and Consumer Discretionary (≈15%). The fund’s performance is sensitive to the U.S. interest-rate environment-mid-cap value stocks tend to underperform when rates rise sharply-while the momentum tilt can boost returns in bullish cycles. Over the past 12 months, XMVM has delivered a total return of about 9.2%, outpacing the broader S&P MidCap 400’s 7.5% return, suggesting the combined factor approach added incremental alpha in a moderate-growth backdrop.
If you want a deeper, data-driven look at how XMVM’s factor exposures compare to peers, a quick browse of ValueRay’s analytical dashboards can help you spot any hidden risks or upside before you decide.
What is the price of XMVM shares?
Over the past week, the price has changed by +5.58%, over one month by +5.84%, over three months by +17.44% and over the past year by +23.70%.
Is XMVM a buy, sell or hold?
What are the forecasts/targets for the XMVM price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | - | - |
| Analysts Target Price | - | - |
| ValueRay Target Price | 81.7 | 16.8% |
XMVM Fundamental Data Overview February 04, 2026
EBIT TTM = 0.0 USD
EBITDA TTM = 0.0 USD
Long Term Debt = unknown (none)
Short Term Debt = unknown (none)
Debt = unknown
Net Debt = unknown
Enterprise Value = 383.5m USD (383.5m + (null Debt) - (null CCE))
Interest Coverage Ratio = unknown (Ebit TTM 0.0 / Interest Expense TTM 0.0)
EV/FCF = unknown (FCF TTM 0.0)
FCF Yield = 0.0% (FCF TTM 0.0 / Enterprise Value 383.5m)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 0.0) / Revenue TTM)
Tobins Q-Ratio = unknown (Enterprise Value 383.5m / Total Assets none)
Interest Expense / Debt = unknown (Interest Expense 0.0 / Debt none)
Taxrate = 21.0% (US default 21%)
NOPAT = 0.0 (EBIT 0.0 * (1 - 21.00%))
Current Ratio = unknown (Total Current Assets none / Total Current Liabilities none)
Debt / Equity = unknown (Debt none)
Debt / EBITDA = unknown (Net Debt none / EBITDA 0.0)
Debt / FCF = unknown (Net Debt none / FCF TTM 0.0)
Total Stockholder Equity = 0.0 (from calculated bookValueOfEquity)
RoA = unknown (Net Income 0.0 / Total Assets none)
RoE = unknown (Net Income TTM 0.0 / Total Stockholder Equity 0.0)
RoCE = unknown (EBIT 0.0 / Capital Employed )
RoIC = unknown (NOPAT 0.0, Invested Capital 0.0, EBIT 0.0)
WACC = 9.23% (E(383.5m)/V(383.5m) * Re(9.23%) + (debt-free company))
Discount Rate = 9.23% (= CAPM, Blume Beta Adj.)
Fair Price DCF = unknown (Cash Flow 0.0)